ClinicalTrials.gg
RecruitingNCT07177794EC-CRT-008Updated Apr 21, 2026

Consolidation of Toripalimab and Capecitabine After Chemoradiotherapy in ESCC

A Phase 3 interventional study of toripalimab and capecitabine in Esophageal Cancer and Chemoradiotherapy, sponsored by Sun Yat-sen University. Recruiting at 1 site in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-04-21.

Primary conditionEsophageal Squamous Cell CarcinomaRegistry: Esophageal NeoplasmsReclassifiedWhy we changed it
Registry
Esophageal Neoplasms — the first condition term the registry derived for this study.
ClinicalTrials.gg
Esophageal Squamous Cell Carcinoma
Why
  1. The study's title name Esophageal Squamous Cell Carcinoma, a narrower term within Esophageal Neoplasms.
Confidence
High: the new condition is named in the study's own title. Of 46 hand-checked studies reclassified this way, 72% were exactly right and 89% in the right disease family; the registry's first term was right for 4% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Sun Yat-sen University · Phase 3, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Sep 2025; still recruiting 1 year 2 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
242
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 18 studies testing toripalimab in Esophageal Squamous Cell Carcinoma — 10 open to participants now, 11 under way, 4 of them phase 3. toripalimab · Esophageal Squamous Cell Carcinoma.

Planned enrollment
4th of 18
242 · median 69
Started
2025
with 3 others
Phase 3
3 of 18
2 open now
Primary completion
2028-05
later than 8 of 10 live
Registered
13th of 18
by date
Lead sponsor
2 of 18
Sun Yat-sen University

Among the 18 studies testing toripalimab in Esophageal Squamous Cell Carcinoma, this one is the 4th largest by planned enrollment, is one of 4 that started in 2025, is one of 3 in phase 3, reaches primary completion later than 8 of the 10 other live ones, and was the 13th registered.

Esophageal Squamous Cell Carcinoma

678 studies on the registry are indexed under Esophageal Squamous Cell Carcinoma; 269 are open to participants now.

Browse Esophageal Squamous Cell Carcinoma studies →

Open to participants now

10 of the 18 studies testing toripalimab in Esophageal Squamous Cell Carcinoma are open now, in 3 countries. Recruiting first, the newest first:

4 more — sign in →

By country, each count listing its studies:

All 10 open studies →

Where they have run

About toripalimab

toripalimab: first FDA approval 2023 (LOQTORZI), first EMA approval 2024. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 180 Esophageal Squamous Cell Carcinoma studies recruiting now, 83 (46%) set no upper age limit and 76 (42%) stop at 75 or younger; 3 take children under 18; 8 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 18 studies testing toripalimab in Esophageal Squamous Cell Carcinoma, or all of them as a file.
02

Study summary

Definitive chemoradiotherapy (CRT) is the standard treatment for locally advanced unresectable esophageal cancer, but its efficacy remains unsatisfactory. More importantly, there is a lack of effective consolidation treatment after CRT, resulting in a high recurrence rate. Our previous prospective phase II trial (EC-CRT-001) demonstrated that the addition of toripalimab to definitive CRT improved the complete response rate in patients with locally advanced esophageal squamous cell carcinoma (ESCC), showing potential for enhanced long-term survival with a manageable safety profile. Nevertheless, the risk of recurrence requires further reduction. Metronomic capecitabine chemotherapy can modulate the tumor immune microenvironment and may synergize with PD-1 antibodies to enhance antitumor efficacy, potentially further prolonging survival in ESCC. Based on current research advances and our preliminary findings, this randomized, controlled, multicenter, phase III clinical trial aims to evaluate the efficacy and safety of toripalimab combined with capecitabine as maintenance therapy for patients with locally advanced ESCC who have not progressed after definitive CRT.

03

Conditions studied

  • Esophageal Cancer
  • Chemoradiotherapy

Browse trials for

Keywords

  • Esophageal squamous cell carcinoma
  • definitive chemoradiotherapy
  • maintenance therapy
  • Toripalimab
04

In context

Esophageal Squamous Cell Carcinoma Reclassified

678 studies on the registry are indexed under Esophageal Squamous Cell Carcinoma; 269 are open to participants now.

This study's planned enrollment of 242 is above the median of 64 across 564 interventional studies indexed under Esophageal Squamous Cell Carcinoma.

Browse Esophageal Squamous Cell Carcinoma studies →

Lead sponsor

Sun Yat-sen University is the lead sponsor of 1,695 studies on the registry; 622 are open to participants now.

Compared within Esophageal Squamous Cell Carcinoma, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Esophageal Neoplasms. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. confirmed squamous cell carcinoma of the esophagus;
  2. Locally advanced esophageal cancer classified as stage I-IVA (inoperable or patient declined surgery) or stage IVB thoracic esophageal cancer with supraclavicular lymph node only (AJCC 8th edition) prior to treatment;
  3. Completion of definitive concurrent chemoradiotherapy without disease progression; radiotherapy dose of 50-50.4 Gy using conventional fractionation and IMRT technique; concurrent platinum- or taxane-based doublet chemotherapy during radiotherapy; ≤4 cycles of induction chemotherapy allowed prior to radiotherapy; /PD-L1 antibody therapy permitted during induction chemotherapy and radiotherapy; no therapy received;
  4. Enrollment window: within 1-42 days after completion of chemoradiotherapy;
  5. Age 18-75 years;
  6. Estimated >6 months;
  7. performance status ≤ 2;
  8. The function of important organs meets the following requirements: a. white blood cell count (WBC) ≥3.5×109/L, (ANC) ≥1.5×109/L; b. ≥75×109/L; c. ≥9g/dL; d. serum albumin ≥2.8g/dL; e. total ≤1.5×, , AST and/or AKP ≤2.5×ULN; f. serum creatinine ≤1.5×ULN or rate >60 mL/min;
  9. Ability to understand the trial details and has provided written .

Exclusion criteria

Exclusion Criteria:

  1. Patients who have received antitumor therapy (including chemotherapy, surgery, immunotherapy, targeted therapy, etc.) after completion of chemoradiotherapy;
  2. Stage IVb patients with to solid organs (e.g., liver, bone, lung, brain, adrenal gland, peritoneum, etc.) at initial diagnosis;
  3. Known or suspected allergy to the drug(s) or any agent related to the trial regimen;
  4. Presence of esophageal fistula and/or esophageal hemorrhage prior to enrollment;
  5. Disease progression after chemoradiotherapy;
  6. ≥Grade 2 radiation pneumonitis prior to enrollment;
  7. History of ≥ Grade 3 immune-related adverse events prior to enrollment;
  8. Prior treatment with targeted drugs;
  9. History of other malignant tumors besides esophageal cancer, except for non-melanoma skin cancer, carcinoma in situ of the cervix, papillary thyroid carcinoma, or cured early-stage prostate cancer;
  10. Patients with severe cardiac, pulmonary, hepatic, or renal dysfunction, hematopoietic system diseases, cachexia, or other conditions that make them unfit for chemotherapy;
  11. Female patients who are pregnant or breastfeeding;
  12. Inability to provide due to psychological, familial, social, or other factors;
  13. Presence of CTC grade ≥2 peripheral neuropathy;
  14. Patients with a history of diabetes for more than 10 years and poorly controlled blood glucose levels;
  15. History of disease or autoimmune disorders (e.g., colitis, systemic lupus erythematosus, rheumatoid arthritis, uveitis, hypophysitis, hyperthyroidism; not limited to these diseases or syndromes), immunodeficiency history, including positivity, or other acquired/congenital immunodeficiency disorders, or history of organ transplantation or bone marrow transplantation;
  16. History of interstitial lung disease or non-infectious pneumonia;
  17. Active (HBV DNA ≥2000 IU/mL or 10⁴ copies/mL) or (HCV antibody positive with HCV-RNA above the lower limit of detection);
  18. Any unstable condition that may jeopardize patient safety or compliance.
Terms in these criteria, in plain language(20)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

06

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
242 participants (estimated)

Study arms

  • Experimental
    Arm A

    Patients will receive toripalimab combined with metronomic capecitabine, with a maximum treatment duration of one year (toripalimab 240 mg, IV drip, Q3W, for 16 cycles; capecitabine 500 mg, twice daily, orally).

    Drug: toripalimab · Drug: capecitabine

  • No intervention
    Arm B

    Patients will undergo conventional observation and follow-up.

Interventions

  • Patients will receive toripalimab with a maximum treatment duration of one year (240 mg, IV drip, Q3W, for 16 cycles).

    Also known as: JS001

  • Patients will receive metronomic capecitabine, with a maximum treatment duration of one year (500 mg, twice daily, orally).

    Also known as: Xeloda

07

What researchers measure

Primary outcomes

  1. Progression-free survival

    Three-year follow-up from the date of enrollment to the date of disease progression or last follow-up

    Time frame: From date of enrollment until the date of death from any cause or the date of first documented disease progression whichever came first, assessed up to 36 months

Secondary outcomes

  1. Overall survival

    Three-year follow-up from the enrollment to the date of death from any cause or date of lost follow-up

    Time frame: From date of enrollment until the date of death from any cause or the date of last follow-up, whichever came first, assessed up to 36 months

  2. Clinical complete response

    Tumor response was evaluated 14-16 weeks after the completion of radiotherapy based on CT or PET-CT scans, and endoscopy with biopsies.

    Time frame: 14-16 weeks after the completion of radiotherapy

  3. Treatment-related adverse events

    Incidence of treatment-related adverse events as assessed by CTCAE v4.0.

    Time frame: From date of enrollment to the date of last follow-up, assessed up to 36 months.

Other outcomes

  1. Correlation between immune signature and overall survival

    The correlation between pretreatment immune signature (PD-L1, CD8, CTLA-4, CD56, and CD68) by mIHC and overall survival.

    Time frame: From date of enrollment to the date of last follow-up, assessed up to 36 months.

  2. Correlation between dynamic change of ctDNA and overall survival

    The correlation between dynamic change of ctDNA during treatment and survival outcomes.

    Time frame: From date of enrollment to the date of last follow-up, assessed up to 36 months.

08

Study locations

1 of 1 sites recruiting
09

References and documents

Publications

  • Zhu Y, Wen J, Li Q, Chen B, Zhao L, Liu S, Yang Y, Wang S, Lv Y, Li J, Zhang L, Hu Y, Liu M, Xi M. Toripalimab combined with definitive chemoradiotherapy in locally advanced oesophageal squamous cell carcinoma (EC-CRT-001): a single-arm, phase 2 trial. Lancet Oncol. 2023 Apr;24(4):371-382. doi: 10.1016/S1470-2045(23)00060-8. PubMed 36990609 ↗
  • Bando H, Kumagai S, Kotani D, Mishima S, Irie T, Itahashi K, Tanaka Y, Habu T, Fukaya S, Kondo M, Tsushima T, Hara H, Kadowaki S, Kato K, Chin K, Yamaguchi K, Kageyama SI, Hojo H, Nakamura M, Tachibana H, Wakabayashi M, Fukui M, Fuse N, Koyama S, Mano H, Nishikawa H, Shitara K, Yoshino T, Kojima T. Atezolizumab following definitive chemoradiotherapy in patients with unresectable locally advanced esophageal squamous cell carcinoma - a multicenter phase 2 trial (EPOC1802). Nat Cancer. 2025 Mar;6(3):445-459. doi: 10.1038/s43018-025-00918-1. Epub 2025 Feb 19. PubMed 39972105 ↗
  • Jia R, Shan T, Zheng A, Zhang Y, Lu P, Zhang G, Wang F, Xu Z, Zheng G, Tang D, Zhang W, Li W, Li R, Guo Y, Liu L, Luo X, Zheng Y, Chang Z, Wang Q, Wang X, Yuan X, Kong G, Li S, Yang R, Zhou D, Ren J, Yin W, Li J, Zhang J, Wang Z, Sheng M, Xu B, Li L, Liu X, Lu Z, Wan L, Zhou F, Gao S. Capecitabine or Capecitabine Plus Oxaliplatin Versus Fluorouracil Plus Cisplatin in Definitive Concurrent Chemoradiotherapy for Locally Advanced Esophageal Squamous Cell Carcinoma (CRTCOESC): A Multicenter, Randomized, Open-Label, Phase 3 Trial. J Clin Oncol. 2024 Jul 10;42(20):2436-2445. doi: 10.1200/JCO.23.02009. Epub 2024 May 6. PubMed 38710003 ↗

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Sep 2025 (actual). Primary completion is estimated for May 2028, 32 months after the start.

Of 44 phase 3 interventional studies under Esophageal Squamous Cell Carcinoma, half reached primary completion within 66 months of starting (the median), counting those still running; a quarter within 37 and three quarters within 76. This study's planned 32 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 10, 2025
First posted
Sep 17, 2025
StartActual
Sep 10, 2025
Primary completionEst.
May 31, 2028
CompletionEst.
May 31, 2030
Last update
Apr 21, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 21, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT07177794
Collaborators
First Affiliated Hospital, Sun Yat-Sen University, Fifth Affiliated Hospital, Sun Yat-Sen University, Zhongshan People's Hospital, Guangdong, China
Responsible party
Mian XI (Professor, Sun Yat-sen University) — Principal investigator
First posted
Sep 17, 2025
Start date
Sep 10, 2025
Primary completion
May 31, 2028 (estimated)
Completion
May 31, 2030 (estimated)
Last update
Apr 21, 2026

Study contacts

Mian Xi, MD
Contact
ximian@sysucc.org.cn
862087343385
Mian Xi, MD
principal investigator · Sun Yat-Sen University Cancer Center

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Toripalimab · Capecitabine

Start the discussion